SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Kronox Lab Sciences Ltd (KRONOX)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 544187 NSE: KRONOX Chemicals | Small Cap | Kronox Lab Sciences Share Price

₹132.75 -1.30 (-0.97%)

As on 04-Jun'26 16:59

Kronox Lab Sciences Ltd (KRONOX)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 544187 NSE: KRONOX Chemicals | Small Cap | Kronox Lab Sciences Share Price

₹132.75 -1.30 (-0.97%)

As on 04-Jun'26 16:59

Key Metrics
Valuation Multiples
Market Cap
₹493 Cr.
Current Price
₹132.8
52-Week Low / High
₹96 / 207
TTM EPS
₹7.5
TTM Sales
₹101 Cr.
Book Value per Share
₹31.3
P/E Ratio
17.81
Lower than its 5-year historical median
Industry PE
50.2
Price to Book (P/B)
4.24
Lower than its 5-year historical median
Price to Sales (P/S)
4.87
Lower than its 5-year historical median
EV/EBITDA
11.29
Lower than its 5-year historical median
Dividend Yield
0.35%
Profitability Efficiency
Return on Equity (ROE)
32.56%
Outperforms industry median
Return on Capital Employed (ROCE)
43.82%
Outperforms industry median
Return on Assets (ROA)
29.61%
Operating Profit Margin
33.1%
Net Profit Margin
25.42%
Gross Profit Margin
35.6%
Growth Momentum
1-yr vs 3-yr growth
Sales Growth (1 Year)
Improving versus 3-year growth rate
11.5%
Operating Profit Growth (1 Year)
Slowing versus 3-year growth rate
16.98%
Net Profit Growth (1 Year)
Slowing versus 3-year growth rate
19.3%
Asset Quality
Promoter Holding
74.21%
Pledged shares (%) of Promoter's holding (%)
0.00%
Reserves
₹79 Cr.
Equity
₹37.1 Cr.
Face Value
₹10
All Time Low / High
₹96.00 / 228.55

Kronox Lab Sciences stock performance

Key Ratios
mw4me loader

Check Before You Invest

Valuation

Fair

Price Trend

Semi Strong
Q.1 Is Kronox Lab Sciences Ltd a good quality company?
Kronox Lab Sciences Ltd is a good quality company, based on a consistently good multi-year financial track record.

This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.

We have analysed the performance of the company on the following:

  • How has it performed on generating Profits?

    By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.

  • How efficiently has it utilized Capital?

    By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.

  • How is it managing its Debt?

    By checking its Debt to Equity and Cash Flow from Operations.

How does Kronox Lab Sciences Ltd performance compare with that of its Peers?
Q.1 Revenue growth of Kronox Lab Sciences Ltd vs industry peers?
Kronox Lab Sciences Ltd revenue CAGR is 0.00%, compared to the industry median CAGR of 7.53%, indicating slower growth and losing its market share.
Q.1 Promoter shareholding and pledge status of Kronox Lab Sciences Ltd?
Promoters hold 74.21% of the Kronox Lab Sciences Ltd, with 0.00% of their stake pledged, indicating no pledge risk.
Q.1 Stock return of Kronox Lab Sciences Ltd over the last decade?
Over the last 1 year(s), the stock has delivered a CAGR of -5.27% based on the current price.

10 Year X-Ray :

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Kronox Lab Sciences Ltd has performed well in majority of the past ten years indicating its past ten year financial track record is very good

Value Creation

Mar'21Mar'22Mar'23Mar'24Mar'25TTM
ROCE % 50.7%55.3%51.6%51.5%43.8%-
Value Creation
Index
2.63.02.72.72.1-

Growth Parameters

Sales 62.582.395.689.9100101
Sales YoY Gr.-31.7%16.2%-6%11.5%-
Adj EPS 2.53.44.25.76.87.5
YoY Gr.-39.4%23.6%34.7%19.3%-
BVPS (₹) 6.910.312.117.924.331.3
Adj Net
Profit
9.613.415.721.225.328
Cash Flow from Ops. 11.3919.717.430.7-
Debt/CF from Ops. 00.1000-

CAGR

9 Years 5 Years 3 Years 1 Years
Sales NANA6.8%11.5%
Adj EPS NANA25.7%19.3%
BVPSNANA32.9%35.9%
Share Price - - - -22.2%

Key Financial Parameters

Mar'21Mar'22Mar'23Mar'24Mar'25TTM
Return on
Equity %
35.839.93738.232.326.8
Op. Profit
Mgn %
23.72422.731.533.133.7
Net Profit
Mgn %
15.416.316.523.625.227.3
Debt to
Equity
000000
Working Cap
Days
0151146157190139
Cash Conv.
Cycle
069706758122

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'21Mar'22Mar'23Mar'24Mar'25
Sales62829690100
Operating Expenses + 4863746267
Manufacturing Costs44568
Material Costs3447554651
Employee Cost 12233
Other Costs 791275
Operating Profit 1520222833
Operating Profit Margin (%) 23.7%23.9%22.7%31.5%33.1%
Other Income + 11223
Exceptional Items 00000
Interest 00000
Depreciation 22111
Profit Before Tax 1318222934
Tax 35679
Profit After Tax 1014162125
PAT Margin (%) 15.6%16.6%17.2%23.8%25.4%
Adjusted EPS (₹)2.53.54.45.86.9
Dividend Payout Ratio (%)0%0%0%8.70%7.30%

Valuation of Kronox Lab Sciences - Standalone

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

mw4me loader

Analyst's Notes

data not found
No data found!

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'21Mar'22Mar'23Mar'24Mar'25

Equity and Liabilities

Shareholders Fund + 2740456690
Share Capital 00373737
Reserves 274082953
Debt +00000
Long Term Debt00000
Short Term Debt00000
Minority Interest00000
Trade Payables712867
Others Liabilities 44111
Total Liabilities 3756547498

Fixed Assets

Net Fixed Assets +911162628
Gross Block1822263740
Accumulated Depreciation910101112
CWIP 00001
Investments 00000
Inventories58996
Trade Receivables1526191820
Cash Equivalents 23448
Others Assets 5971635
Total Assets 3756547498

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'21Mar'22Mar'23Mar'24Mar'25
Cash Flow From Operating Activity + 119201731
PBT 1318222934
Adjustment 2211-0
Changes in Working Capital -1-72-45
Tax Paid -4-5-6-7-9
Cash Flow From Investing Activity + -3-8-7-17-28
Capex -2-4-8-12-3
Net Investments -2-40-6-27
Others 00112
Cash Flow From Financing Activity + -7-1-130-2
Net Proceeds from Shares 00000
Net Proceeds from Borrowing 00000
Interest Paid -0-0-000
Dividend Paid 0000-2
Others -7-0-1300
Net Cash Flow 11-000

Financial Ratio

PARTICULARSMar'21Mar'22Mar'23Mar'24Mar'25
Ratios
ROE (%)36.2940.5838.5538.4532.56
ROCE (%)50.7155.3251.6351.5243.82
Asset Turnover Ratio1.671.751.731.411.16
PAT to CFO Conversion(x)1.10.641.250.811.24
Working Capital Days
Receivable Days90.2091.5084.7073.5068.40
Inventory Days32.1028.9031.9037.4028.50
Payable Days69.5069.6064.3056.5049

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Kronox Lab Sciences Ltd FAQs

The current trading price of Kronox Lab Sciences on 04-Jun-2026 16:59 is ₹132.8.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 03-Jun-2026 the market cap of Kronox Lab Sciences stood at ₹492.6 Cr

The latest P/E ratio of Kronox Lab Sciences as of 03-Jun-2026 is 17.81.

The latest P/B ratio of Kronox Lab Sciences as of 03-Jun-2026 is 4.24.

The 52-week high of Kronox Lab Sciences is ₹207.4 and the 52-week low is ₹96.00.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Kronox Lab Sciences is ₹101 ( Cr.) .

Past 10 year's financial track record analysis by Moneyworks4me indicates that Kronox Lab Sciences Ltd is a good quality company.

The key valuation ratios of Kronox Lab Sciences Ltd's currently when compared to its past seem to suggest it is in the Fair zone.

The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Kronox Lab Sciences Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.

About Kronox Lab Sciences Ltd

The company was incorporated on November 18, 2008 as 'Kronox Lab Sciences Private Limited', a private limited company under the Companies Act, 1956, pursuant to a certificate of incorporation dated November 18, 2008 issued by the Assistant Registrar of Companies, Gujarat, Dadra and Nagar Haveli. Subsequently, the company was converted into a public limited company pursuant to a resolution passed by its shareholders at an extra-ordinary general meeting held on May 25, 2019 and a fresh certificate of incorporation dated June 11, 2019 was issued by the Registrar of Companies, Ahmedabad consequent upon conversion, recording the change in the name of the company to 'Kronox Lab Sciences Limited'.   

The company manufactures High Purity Speciality Fine Chemicals for diversified end user industries. Its High Purity Speciality Fine Chemicals are used mainly as (i) reacting agents and raw material in the manufacturing of Active Pharmaceutical Ingredients (APIs); (ii) excipients in pharmaceutical formulations; (iii) reagents for scientific research and laboratory testing; (iv) ingredients in nutraceuticals formulations; (v) process intermediates and fermenting agents in biotech applications; (vi) ingredients in agrochemical formulations; (vii) ingredients in personal care products; (viii) refining agents in metal refineries; and (ix) ingredients in animal health products, amongst others. Its products are manufactured in accordance with industry standards like IP, BP, EP, JP, USP, FCC, LR, AR, GR and ACS in addition to custom manufacturing specifications, which differ from the industry standards, required by its customers in select cases. It manufactures High Purity Speciality Fine Chemicals of various grades in particle sizes ranging from 10 mesh to 100 mesh. Its focus on product development, diversity in product offerings, meeting quality standards and customer specifications and continuous process improvement has led to repeat orders from its customers over the years.

In addition to the manufacturing of products in accordance with various domestic and international standards, it also undertakes custom manufacturing to achieve high levels of purity, as specified by the client, having different purity levels than the prescribed industry standards. Custom manufacturing requires deep domain knowledge, expertise and understanding of the characteristics of each chemical and its compounds, including decreasing the level of existing impurities and the processes to be deployed to reach the desired level of purity. It has set up an in-house research, development and testing laboratory (RDT Laboratory) to develop new products and test its products against the specified industry standards or customer specifications. Its dedicated RDT Laboratory is located in Unit I with the objective to implement a performance-oriented approach with the help of advanced equipment and systems. Its RDT Laboratory is equipped with the necessary facilities to carry out tests required to develop the products. 

Business area of the company

The company is a bulk manufacturer of high purity fine chemicals, in compliance with Reagent, Pharmacopoeia and various Food Grade standards, for the pharmaceutical, nutraceutical, veterinary, food, chemical analysis and other specialty markets. 

Major events:

  • 2008: Incorporation of the company.
  • 2009: Commencement of manufacturing of High Purity Speciality Fine Chemicals at Unit I.
  • 2010: Commenced export of products.
  • 2011: The company expanded its Unit I for manufacturing of High Purity Speciality Fine Chemicals used in pharmaceutical and nutraceutical industries.
  • 2011: The company started manufacturing High Purity Speciality Fine Chemicals to cater to the solar industries.
  • 2014: Acquisition of land along with factory shed for Unit II.
  • 2014: Receipt of FSSC 22000 certification from ISOQAR, UK for Unit I.
  • 2015: Commencement of manufacturing operations at Unit II.
  • 2015: Obtained FSSAI certification for manufacturing of food grade fine chemicals and ingredients.
  • 2017: Receipt of ISO 14001: 2015 & OHSAS 18001:2007 certification in respect of Unit I.
  • 2019: Started manufacturing of products at its Unit III.
  • 2022: Acquisition of land along with factory shed for Unit I and Unit III.
  • 2023: Acquisition of land for proposed Unit IV.


You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×